Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hyperthyroidism Age: Adult |
Dose: Oral – 150-450 mg Frequency: daily in divided doses Duration: 1-2 years Note: Dose reduction is recommended for hepatic impairment. |
|
Indication: Hyperthyroidism Age: Adult Condition: Severe cases |
Dose: Oral – 600-1200 mg Frequency: daily Duration: 1-2 years Note: Initial doses used for severe cases. Dose reduction is recommended for hepatic impairment. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hyperthyroidism Age: Neonates |
Dose: Oral – 2.5-5 mg/kg Frequency: twice daily |
|
Indication: Hyperthyroidism Age: 1 month-1 year |
Dose: Oral – 2.5 mg/kg Frequency: three times daily |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment: Creatinine Clearance less than 10 ml/min |
Dose: Dosage Recommendation – Reduce dose by 50% Note: Renal impairment adjustment |
|
Condition: Renal impairment: Creatinine Clearance 10-50 ml/min |
Dose: Dosage Recommendation – Reduce dose by 25% Note: Renal impairment adjustment |
Administration
- Should be taken with food
- Take at same time each day
Side Effect
- Mild leukopenia
- lupus-like syndrome
- cutaneous vasculitis
- thrombocytopenia
- Skin rash
- urticaria
- arthralgia and fever
- GI discomfort
- vomiting
- headache
- Agranulocytosis
- aplastic anaemia
- liver injury and liver failure
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Anticoagulants (Warfarin, Heparin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban)
|
May potentiate activity
|
|
β-blockers, digitalis glycosides, theophylline
|
Doses may need to be reduced when patient becomes euthyroid
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at controlled room temperature 15°-30°C
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.